Squamous cell carcinoma arising from lupus vulgaris with a >60-year history

Por Miyake, T., Uhara, H., Ishii, N., Okuyama, R.
Publicado no Int Cancer Conf J (2017)

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan

Por Uhara, H., Kiyohara, Y., Tsuda, A., Takata, M., Yamazaki, N.
Publicado no Clin Transl Oncol (2017)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level

Por Sakaizawa, K, Goto, Y, Kiniwa, Y, Uchiyama, A, Harada, K, Shimada, S, Saida, T, Ferrone, S, Takata, M, Uhara, H, Okuyama, R
Publicado em 2012

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma

Por Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., Tokudome, T.
Publicado no Cancer Chemother Pharmacol (2015)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

Por Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., Tokudome, T.
Publicado no Cancer Chemother Pharmacol (2015)